Kailera Therapeutics, Inc. (KLRA) company profile
KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026
$12.20−0.37 (-2.94%)
Close on Nov 17, 2026Market cap $1.58BP/E –Yield –
About Kailera Therapeutics
Pharmaceutical Preparations, SIC 2834
Kailera Therapeutics, Inc. is listed on Nasdaq under the ticker KLRA, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Kailera Therapeutics, Inc.
- Headquarters
- Waltham, MA
- Address
- 180 Third Avenue, 4th Floor 02451
- Phone
- (508) 440-9475
- Website
- kailera.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- KLRA
- Exchange
- Nasdaq
- IPO date
- Apr 17, 2026
- Shares outstanding
- 130M, Aug 6, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2096997
- CUSIP
- 482931102
- ISIN
- US4829311020
- FIGI
- BBG01Q3NQQJ1
- Share class FIGI
- BBG01Q3NQQK9
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ronald C. Renaud JR | CEO & President, Director | 38,094 |
| Nur Nicholson | Chief Technology Officer | – |
| Kathleen Tregoning | See Remarks | – |
| Paul D. Burgess | See Remarks | – |
| Paula Cloghessy | Chief People Officer | – |
| Jamie Beth Coleman | Chief Commercial Officer | – |
| Scott Akamine | Chief Legal Officer | – |
| Scott M. Wasserman | Chief Medical Officer | – |
| Douglas W. Pagan | Chief Financial Officer | – |
| Frank Clyburn | Director | – |
| Christopher Hite | Director | – |
| John F. Milligan | Director | – |
| Martin Mackay | Director | – |
| Adam Koppel | Director | 16,875,000 |
| Andrew T. Kaplan | Director | 17,857,143 |
| Yuting Liu | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 17, 2026
- Offer price
- $16.00
- Securities offered
- 39,062,500
- Gross proceeds
- $625.00M
- Exchange
- Nasdaq
- First trading day
- Apr 17, 2026
- First-day close
- $26.00+62.5%
- Lock-up ends (est.)
- Oct 14, 2026
“The public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 17, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 14, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?